<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005568" GROUP_ID="STROKE" ID="687704111517422534" MERGED_FROM="" MODIFIED="2008-05-30 12:07:20 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0002" REVMAN_SUB_VERSION="5.0.5" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-05-30 12:07:20 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Dengzhanhua preparations for acute cerebral infarction</TITLE>
<CONTACT MODIFIED="2008-05-30 12:07:20 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="12832" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Guanjian</FIRST_NAME><LAST_NAME>Liu</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>ceuliu@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Evidence-Based Medicine and Clinical Epidemiology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37 Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 85422081</PHONE_1><FAX_1>+86 28 85422253</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-05-30 12:07:20 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="005EFC2982E26AA20035135A8C4A7E62" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Wenzhai</FIRST_NAME><LAST_NAME>Cao</LAST_NAME><EMAIL_1>caowenzhai@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>Zigong No. 1 People's Hospital</ORGANISATION><ADDRESS_1>Zigong Renji Medical Centre</ADDRESS_1><ADDRESS_2>No 42, Shang Yi Jing Yi Zhi Lu</ADDRESS_2><CITY>Zigong</CITY><ZIP>64300</ZIP><REGION>Sichuan Province</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 813 4612298</PHONE_1><FAX_1>+86 813 2100014</FAX_1></ADDRESS></PERSON><PERSON ID="17576" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Weimin</FIRST_NAME><LAST_NAME>Liu</LAST_NAME><EMAIL_1>vikienew@yahoo.com.cn</EMAIL_1><ADDRESS><ORGANISATION>China Academy of Traditional Chinese Medicine</ORGANISATION><ADDRESS_1>No. 16 Dong Zhi Lei Nan Xiao Jie</ADDRESS_1><CITY>Beijing</CITY><ZIP>100700</ZIP><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 10 64014411 2408</PHONE_1><FAX_1>+86 10 64008717</FAX_1></ADDRESS></PERSON><PERSON ID="12346" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Taixiang</FIRST_NAME><LAST_NAME>Wu</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>txwutx@hotmail.com</EMAIL_1><EMAIL_2>txwutx@public.cd.sc.cn</EMAIL_2><ADDRESS><DEPARTMENT>Chinese Cochrane Centre, Chinese EBM Centre</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8542 2081</PHONE_1><PHONE_2>+86 28 8517 6330</PHONE_2><FAX_1>+86 28 8554 2774</FAX_1></ADDRESS></PERSON><PERSON ID="0F6E7E3F82E26AA200C069EC5E7D642A" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Dechao</FIRST_NAME><LAST_NAME>Zhong</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>zhongdechao2000@163.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>Zigong No. 1 People's Hospital</ORGANISATION><ADDRESS_1>Zigong Renji Medical Centre</ADDRESS_1><ADDRESS_2>No 42, Shang Yi Jing Yi Zhi Lu</ADDRESS_2><CITY>Zigong</CITY><ZIP>64300</ZIP><REGION>Sichuan Province</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 813 2121094</PHONE_1><FAX_1>+86 813 2100014</FAX_1></ADDRESS></PERSON><PERSON ID="12832" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Guanjian</FIRST_NAME><LAST_NAME>Liu</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>ceuliu@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Evidence-Based Medicine and Clinical Epidemiology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37 Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 85422081</PHONE_1><FAX_1>+86 28 85422253</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-04-17 11:38:44 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="10" MONTH="3" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="10" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="4" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2006"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="17" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-04-17 11:41:06 +0100" MODIFIED_BY="Hazel Fraser"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Chinese Cochrane Center, Chinese Centre of Evidence-Based Medicine, West China Hospital of Sichuan University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>China Medical Board of New York</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Cochrane Stroke Group</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-05-08 14:26:16 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2008-05-07 14:52:47 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-04-17 11:50:08 +0100" MODIFIED_BY="Hazel Fraser">Dengzhanhua preparations for acute cerebral infarction</TITLE>
<SUMMARY_BODY MODIFIED="2008-05-07 14:52:47 +0100" MODIFIED_BY="Hazel Fraser">
<P>There is no clear evidence that dengzhanhua injections benefit patients with acute cerebral infarction. Dengzhanhua preparations are a traditional herbal drug that are commonly used in China to treat disorders of the blood supply to the heart and brain, including stroke. These compounds have a number of actions which might help reduce disability after stroke. The most common type of stroke is cerebral infarction, which is due to blockage of the blood supply to one part of the brain. This review aimed to include randomised or quasi-randomised trials of dengzhanhua preparations in the treatment of patients with recent cerebral infarction. Nine studies involving 723 participants were included. The studies were of poor quality. Although treatment with dengzhanhua injections appeared to improve neurological function, there was no evidence that treatment improved the chance of being alive and free of disability. This review therefore did not find evidence to support the routine use of dengzhanhua for patients with recent stroke. Further well-designed trials are needed.
<BR/>

</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-04-21 13:25:01 +0100" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND MODIFIED="2008-04-21 13:24:30 +0100" MODIFIED_BY="Hazel Fraser">
<P>Dengzhanhua preparations are widely used in China. Many controlled trials have been undertaken to investigate the efficacy of dengzhanhua preparations in the treatment of acute cerebral infarction.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-04-21 13:24:38 +0100" MODIFIED_BY="Hazel Fraser">
<P>To assess whether dengzhanhua preparations are effective and safe at improving outcomes in patients with acute cerebral infarction.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-04-17 12:02:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group Trials Register (last searched October 2007), the Chinese Stroke Trials Register (last searched June 2006), the trials register of the Cochrane Complementary Medicine Field (last searched June 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>, Issue 2 2006), MEDLINE (1966 to June 2006), EMBASE (1980 to June 2006), AMED (the Allied and Complementary Medicine Database, 1985 to June 2006), the China Biological Medicine Database (CBM-disc, 1979 to June 2006), and Chinese Knowledge Infrastructure (CNKI,1994 to October 2007). We also searched the reference lists of relevant articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-04-21 13:24:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomised and quasi-randomised controlled clinical trials of dengzhanhua preparations regardless of duration, dosage and route of administration in patients with confirmed acute cerebral infarction.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-04-17 12:02:26 +0100" MODIFIED_BY="Hazel Fraser">
<P>Two review authors independently applied the inclusion criteria, assessed trial quality, and extracted the data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-04-21 13:25:01 +0100" MODIFIED_BY="Hazel Fraser">
<P>We included nine trials, all conducted in China, involving 723 participants. The method of randomisation and concealment was poorly described. The included trials compared dengzhanhua injection plus routine therapy with routine therapy alone. Patients were enrolled up to one week after the onset of stroke. No trials reported data on the pre-specified primary or secondary outcomes. In a post-hoc comparison of dengzhanhua injection plus routine therapy versus routine therapy alone, dengzhanhua injection showed a statistically significant benefit on the outcome 'marked neurologic improvement' (relative risk 1.53; 95% confidence interval 1.36 to 1.72). No serious adverse effects were reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-04-17 13:17:22 +0100" MODIFIED_BY="Hazel Fraser">
<P>Due to the generally low methodological quality and small sample size of the included trials in this systematic review, we could not draw a firm conclusion.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-05-07 15:00:43 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND MODIFIED="2008-05-07 14:57:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>A stroke is an acute impairment of focal brain function which can be due to a variety of pathologic alterations in intracranial or extracranial blood vessels and can result in death or physical disability (<LINK REF="REF-Goldman-2000" TYPE="REFERENCE">Goldman 2000</LINK>). In China, stroke is the second most common cause of death in urban areas and the third most common in rural areas (<LINK REF="REF-MOH-PRC-1999" TYPE="REFERENCE">MOH PRC 1999</LINK>). It is estimated that 15 million new cases of stroke and five million deaths occur each year worldwide (<LINK REF="REF-WHO-2005" TYPE="REFERENCE">WHO 2005</LINK>). In the United States, stroke is the third most common cause of death, accounting for more than one in every 15 deaths in 2001. Approximately 700,000 Americans suffer a new or recurrent stroke each year (<LINK REF="REF-AHA-2004" TYPE="REFERENCE">AHA 2004</LINK>). Acute ischaemic stroke accounts for 80% of all strokes (<LINK REF="REF-Jeffrey-2005" TYPE="REFERENCE">Jeffrey 2005</LINK>). Neurological symptoms and signs evolve after stroke onset in 25% to 40% of patients. Severe clinical manifestations in the acute phase usually indicate an increased risk of death and physical disability (<LINK REF="REF-Vila-2000" TYPE="REFERENCE">Vila 2000</LINK>).</P>
<P>No medication has yet been confirmed to have neuroprotective effects for acute ischaemic stroke (<LINK REF="REF-Adams-2003" TYPE="REFERENCE">Adams 2003</LINK>). Management of patients with acute ischaemic stroke with thrombolytic therapy carries the risk of catastrophic intracerebral haemorrhage (<LINK REF="REF-Hommel-1995" TYPE="REFERENCE">Hommel 1995</LINK>). Although intravenous recombinant tissue plasminogen activator (rt-PA) in cerebral infarction can improve functional outcome of patients within three hours of stroke onset, it cannot be used as a routine therapy outside special units (<LINK REF="REF-NINDS-1995" TYPE="REFERENCE">NINDS 1995</LINK>). Heparin has no benefit in reducing mortality in patients with acute ischaemic stroke (<LINK REF="REF-Gubitz-2004" TYPE="REFERENCE">Gubitz 2004</LINK>). Therefore, we have to seek a more effective therapy for these patients.</P>
<P>Dengzhanhua (Breviscapine) injection is extracted from Erigeron breviscapus (Vant.) (Erigeron breviscapus is a plant which mainly grows in southwest China; 'Vant.' means compositae). Dengzhanhua injection is a traditional herbal drug for cardio-cerebral vascular diseases recorded by the Chinese Drug Dictionary 1977 edition. The main active components of dengzhanhua injection are Scutellarin and Pyromeconic acid (<LINK REF="REF-Yang-2001" TYPE="REFERENCE">Yang 2001</LINK>; <LINK REF="REF-Zhang-2000" TYPE="REFERENCE">Zhang 2000</LINK>).</P>
<P>Recent pharmacological experiments proved that dengzhanhua has several possible modes of action. The compound can inhibit platelet 5-HT release and platelet destruction could be reduced in vivo (<LINK REF="REF-Wang-1989" TYPE="REFERENCE">Wang 1989</LINK>). In addition, dengzhanhua can also reduce brain oedema, inhibit myeloperoxidase (MPO) activity and the expression of intercellular adhesion molecule 1 (ICAM-1). Breviscapine attenuates brain oedema and neutrophil infiltration after cerebral ischaemia reperfusion (<LINK REF="REF-He-2004" TYPE="REFERENCE">He 2004</LINK>). More important, there is evidence that dengzhanhua can protect against reperfusion injury after ischaemia through inhibiting protein kinase C (PKC), raised blood flow and maintaining the activity of Na+, K+ -A TPase and Ca2+-ATPase in the brain (<LINK REF="REF-Chen-1998" TYPE="REFERENCE">Chen 1998</LINK>). Dengzhanhua can therefore have effects on the occurrence of, and further neuronal impairment after acute cerebral infarction.</P>
<P>There are several preparations available such as troche (buccal tablet) (20 mg) and injection (5 mg per 2 ml). It can be taken orally 40 mg three times per day, or 5 mg twice a day intramuscular, or 5 mg to 10 mg in 5% to 10% glucose solution intravenously for acute ischaemic stroke (<LINK REF="REF-Ren-2002" TYPE="REFERENCE">Ren 2002</LINK>).</P>
<P>Though dengzhanhua treatment and its method of manufacture are widely accepted in China, the constituents of the pharmacological preparations used in the trials cannot be specified precisely. The main component is Breviscapine, but there may be still other components which are not clear yet. This is in marked contrast to industrially manufactured pharmacological agents used in Western medicine, in which the chemical constituents and their quantities (and the percentage of any impurities or contaminants) are very precisely known, and the variation between different production batches is kept within specified limits. Variation between formulations and batches of treatments is an inevitable consequence of the nature of Chinese Traditional Medicine; it is a factor that may contribute to any heterogeneity between different study results.</P>
<P>The effects, both beneficial and adverse, of dengzhanhua on acute cerebral infarction need to be reviewed systematically and appraised critically to inform current practice and direct the continued search for new treatment regimens.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-04-21 13:26:26 +0100" MODIFIED_BY="Hazel Fraser">
<P>To assess the effect of dengzhanhua preparations for acute cerebral infarction compared with placebo or open control, and to evaluate the side effects and adverse events of dengzhanhua preparations.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES MODIFIED="2008-04-17 13:26:37 +0100" MODIFIED_BY="Hazel Fraser">
<P>We included randomised and quasi-randomised controlled clinical trials (that is, allocation using alternation, the sequence of admission, case record numbers, dates of birth, or day of the week).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Participants were male or female of any age or ethnic origin with acute cerebral infarction in either the carotid or vertebral artery territory, defined by brain computerised tomography (CT) or magnetic resonance imaging (MRI) scan. Trials restricted to patients with transient ischaemic attacks (TIA) or intracranial haemorrhage were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-04-21 13:26:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>We included trials of dengzhanhua regardless of duration, dosage and route of administration. We compared dengzhanhua with placebo or no treatment. However, trials of dengzhanhua plus another treatment versus the other treatment alone in order to assess dengzhanhua were also included.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-04-21 13:26:50 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>(1) Death from any cause at the end of the scheduled follow-up period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<P>(1) Death or dependence at the end of follow-up period.<BR/>(2) Quality of life if used in the included trials.<BR/>(3) Adverse events: bleeding, nausea, vomiting, abdominal pain, diarrhoea, allergic reaction, or other serious adverse event caused by dengzhanhua. We evaluated the number of patients developing at least one severe adverse event listed above.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-05-07 15:00:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>See: 'Specialized register' section in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>We searched the Cochrane Stroke Group Trials Register, which was last searched by the Review Group Co-ordinator in October 2007, the Chinese Stroke Trials Register (last searched June 2006), and the trials register of the Cochrane Complementary Medicine Field (last searched June 2006). In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>, Issue 2, 2006), MEDLINE (1966 to June 2006) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), EMBASE (1980 to June 2006), AMED (the Allied and Complementary Medicine Database, 1985 to June 2006) and the China Biological Medicine Database (CBM-disc, 1979 to June 2006), which is a database of Chinese biomedical research literature. At the peer review stage of this review, a reviewer suggested we search the Chinese Knowledge Infrastructure for additional studies. Though this was not included in the protocol, we searched CNKI (1994 to October 2007).</P>
<P>We also searched the reference lists of relevant articles.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-05-07 14:54:07 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">Study selection</HEADING>
<P>Two authors independently screened every title, abstract, and full text of study reports. We included those studies that met the pre-determined inclusion criteria. We resolved any disagreements on the selection of studies for inclusion by consensus discussion or with a third party if necessary. We tried to obtain missing data from the study authors where possible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment of studies</HEADING>
<P>According to the empirical evidence, we assessed the methodological quality as described by The Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Minimisation of selection bias</HEADING>
<UL>
<LI>Was the randomisation procedure adequate?</LI>
<LI>Was the allocation concealment adequate?</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Minimisation of performance bias</HEADING>
<UL>
<LI>Were the patients and people administering the treatment blind to the intervention?</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Minimisation of attrition bias</HEADING>
<UL>
<LI>Were withdrawals and dropouts completely described?</LI>
<LI>Was analysis by intention-to-treat?</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Minimisation of detection bias</HEADING>
<UL>
<LI>Were outcome assessors blind to the intervention?</LI>
</UL>
<P>Based on these criteria, we broadly subdivided the studies into the following three categories.<BR/>A - all quality criteria met: low risk of bias.<BR/>B - one or more of the quality criteria only partly met: moderate risk of bias.<BR/>C - one or more criteria not met: high risk of bias.</P>
<P>This classification was to be used as the basis of a sensitivity analysis. Since the studies were all of the same poor quality, we did not perform a sensitivity analysis.<BR/>
<BR/>Two authors (Cao, Liu) assessed each trial independently. We resolved disagreements, if necessary, by recourse to a third author (Wu). In cases of further disagreement, we consulted the rest of the group and a judgment was made based on consensus.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>For binary outcomes, we extracted the number of events and the total number in each group. For continuous outcomes, we abstracted or imputed means, standard deviations and sample sizes for each group. Two authors (Cao, Liu) independently extracted data concerning details of study population, intervention and outcomes using a data extraction form specifically designed for this review. The data extraction form included the following items.<BR/>(1) General information: published or unpublished, title, authors, reference or source, contact address, country, urban or rural, language of publication, year of publication, duplicate publications, sponsor, setting.<BR/>(2) Trial characteristics: design, duration of follow up, method of randomisation, allocation concealment, blinding (patients, people administering treatment, outcome assessors).<BR/>(3) Intervention(s): intervention(s) (dose, route and timing), comparison intervention(s) (dose, route and timing) and co-medication (dose, route and timing).<BR/>(4) Patients: exclusion criteria, total number and number in comparison groups, age (adults), baseline characteristics, diagnostic criteria, similarity of groups at baseline (including any co-morbidity), assessment of compliance, withdrawals and losses to follow up (reasons, description), subgroups.<BR/>(5) Outcomes: outcomes specified above, any other outcomes assessed, other events, length of follow up, quality of reporting of outcomes.<BR/>(6) Results: for outcomes and times of assessment (including a measure of variation) converted to measures of effect specified below if necessary, intention-to-treat analysis.</P>
<P>We resolved disagreements in data extraction by consensus, referring to the original article. If necessary, we sought information from the study authors. If there was continued disagreement we consultated a third author (Wu).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>We included data in a meta-analysis if they were available, of sufficient quality and sufficiently similar. We expected both dichotomous data and continuous data. Only dichotomous data were extracted from included studies and expressed as relative risk (RR). We did not perform combination analyses for overall results since different comparators were used in variety studies. We assessed heterogeneity by using the I-square (I<SUP>2</SUP>) statistic. We used a random-effects model for combination analysis in each subgroup. We did not perform a publication bias analysis as there were no more than three studies included in a subgroup.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>We had planned to perform the following subgroup analyses.</P>
<UL>
<LI>Treatment form (injection, tablet, granules, extract, capsule, oral liquid, dripping pills, buccal tablets).</LI>
<LI>Course of treatment, combined medication, route of administration, dosage.</LI>
<LI>The subgroup analyses were to be the time from stroke onset to treatment, the duration of follow up (four weeks versus more than four weeks), patients with Asian ethnic origin compared with ones non-Asian origin, dose (low, medium, high based on the data). We planned to explore reasons for heterogeneity in the included studies and, if necessary, we also planned to do sensitivity analyses to examine the effects of excluding study subgroups, such as those studies with lower methodological quality.</LI>
</UL>
<P>However, it was not possible to perform the subgroup analyses because of the lack of data.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION MODIFIED="2008-05-07 09:05:50 +0100" MODIFIED_BY="[Empty name]">
<P>Through electronic searches and screening of reference lists of articles we identified 43 potentially relevant references. At the peer review stage of this review, we searched the Chinese Knowledge Infrastructure for additional studies and found other 30 potentially relevant references. Among these, we excluded 52 irrelevant references (mainly experimental studies), which left us with 21 potentially eligible trials, of which nine (<LINK REF="STD-Feng-2005" TYPE="STUDY">Feng 2005</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>; <LINK REF="STD-Li-1996" TYPE="STUDY">Li 1996</LINK>; <LINK REF="STD-Liu-2004a" TYPE="STUDY">Liu 2004a</LINK>; <LINK REF="STD-Peng-2005" TYPE="STUDY">Peng 2005</LINK>; <LINK REF="STD-Wang-2004" TYPE="STUDY">Wang 2004</LINK>; <LINK REF="STD-Wang-2005" TYPE="STUDY">Wang 2005</LINK>; <LINK REF="STD-Wen-2003" TYPE="STUDY">Wen 2003</LINK>; <LINK REF="STD-Yu-2005" TYPE="STUDY">Yu 2005</LINK>) were included, containing 723 patients with acute ischaemic stroke. Details of the included trials can be found in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> section. We excluded 12 studies (<LINK REF="STD-Bai-2002" TYPE="STUDY">Bai 2002</LINK>; <LINK REF="STD-Chu-2003" TYPE="STUDY">Chu 2003</LINK>; <LINK REF="STD-Fang-1996" TYPE="STUDY">Fang 1996</LINK>; 
<LINK REF="STD-Liu-1999" TYPE="STUDY">Liu 1999</LINK>; 
<LINK REF="STD-Li-2000" TYPE="STUDY">Li 2000</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-Lu-2002" TYPE="STUDY">Lu 2002</LINK>; <LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>; <LINK REF="STD-Wang-1987" TYPE="STUDY">Wang 1987</LINK>; <LINK REF="STD-Xu-1999" TYPE="STUDY">Xu 1999</LINK>; <LINK REF="STD-Yang-2000" TYPE="STUDY">Yang 2000</LINK>; <LINK REF="STD-Zhang-2002" TYPE="STUDY">Zhang 2002</LINK>) because they compared dengzhanhua with unproven drugs (<I>see </I>
<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
<P>The included trials were conducted in China. The average age of participants ranged from 54 to 85 years. All the trials enrolled more males than females, except one trial (<LINK REF="STD-Li-1996" TYPE="STUDY">Li 1996</LINK>), which included more females. All the trials described the inclusion criteria. All the trials routinely performed a CT or MRI head scan in patients to exclude haemorrhage before randomisation.</P>
<P>All included trials studied dengzhanhua injection to assess the effect of dengzhanhua, and compared dengzhanhua and routine therapy in the treatment group with routine therapy alone in the control group. The doses of dengzhanhua ranged from 16 ml to 40 ml, 30 mg to 75 mg respectively. The course of treatment ranged from 10 days to 30 days. The dengzhanhua injection used in the trials was administered once a day for one course of treatment.</P>
<P>None of the trials reported follow up after the termination of the treatment period. Neither deaths nor adverse events were reported. None of the trials included quality of life as an outcome measure.<BR/>

<BR/>
None of the trials reported the outcome measures that we used in our study protocol. The outcome measures used in the included trials were the measurement of neurologic deficit using the nationally approved outcome measures which were similar to the National Institute of Health Stroke Scale. We therefore performed a post-hoc analysis on the proportion of patients with marked neurologic improvement after treatment. The measures could concentrate on either specific neurologic dysfunction (such as motor or cognition deficit) or overall neurologic deficit (such as the National Institute of Health Stroke Scale, which involves consciousness, vision, gaze, motor and other impaired neurological function).</P>
<P>As the studies were all of poor quality, we did not perform a sensitivity analysis.
<BR/>

</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-05-07 09:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>Two trials (<LINK REF="STD-Wang-2005" TYPE="STUDY">Wang 2005</LINK>; <LINK REF="STD-Liu-2004a" TYPE="STUDY">Liu 2004a</LINK>) described allocated treatment according to the sequence of admission and hence were quasi-randomised.The remaining seven trials (
<LINK REF="STD-Feng-2005" TYPE="STUDY">Feng 2005</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>; <LINK REF="STD-Li-1996" TYPE="STUDY">Li 1996</LINK>; <LINK REF="STD-Peng-2005" TYPE="STUDY">Peng 2005</LINK>; <LINK REF="STD-Wang-2004" TYPE="STUDY">Wang 2004</LINK>; <LINK REF="STD-Wen-2003" TYPE="STUDY">Wen 2003</LINK>; <LINK REF="STD-Yu-2005" TYPE="STUDY">Yu 2005</LINK>) did not describe the method of allocation or allocation concealment. We tried to contact the original authors to check the randomisation method in detail, but none of authors were contacted successfully. Therefore, the overall quality rating of all the included trials was graded C (high risk of bias). The baseline characteristics of the patients in the included trials showed no significant imbalance between groups. The time from stroke onset to randomisation in all the trials was within one week from onset. No loss to follow up was reported in any trial.
<BR/>

</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-05-07 09:08:23 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Death from any cause at the end of the scheduled follow-up period</HEADING>
<P>None of the trials reported the continued follow up after the termination of the treatment period. None of the trials reported any deaths at all.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Death or dependence at the end of follow-up period</HEADING>
<P>No trials reported any death or dependence at the end of follow-up period. Therefore, death or dependence at the end of the follow-up period was not assessed in the included trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life if used in the included trials</HEADING>
<P>None of the included trials undertook the assessment of quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>None of the trials provided any data regarding adverse events, and no case of serious adverse events such as major extracranial bleeding was reported during the treatment period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.1: Marked neurologic improvement (post-hoc comparison)</HEADING>
<P>Although we were not able to extract any data on the pre-specified primary and main secondary outcomes, we were able to extract data on the proportion of participants with marked neurologic improvement after treatment. This was a post-hoc outcome, and this analysis must therefore be interpreted with caution. All nine trials including randomised data from 723 participants evaluated neurologic dysfunction (divided into six grades from death or deterioration to cure), and we converted these outcomes to dichotomous data (the proportion of patients with at least 45% neurologic improvement). The included trials appeared to show a statistically significant benefit from dengzhanhua compared with control (RR 1.53; 95% CI 1.36 to 1.72); no statistical heterogeneity was detected (I<SUP>2</SUP>= 0%).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-04-21 13:27:51 +0100" MODIFIED_BY="Hazel Fraser">
<P>Though dengzhanhua treatment and its method of manufacture are widely accepted in China, the effects, both beneficial and adverse, of dengzhanhua on acute cerebral infarction needed to be appraised critically. We included nine completed randomised or quasi-randomised controlled trials of dengzhanhua preparations for acute ischaemic infarction. The result of our meta-analysis suggests that dengzhanhua could have potential therapeutic value in the treatment of acute ischaemic infarction. However, due to the generally poor methodological quality of the included trials, we could not make firm conclusions. There are several substantial limitations.</P>
<P>Firstly, published studies from China were found to be different from typical articles published in the Western literature, with key details concerning randomisation and blinding omitted. In our meta-analysis, although all included trials reported the use of randomisation, two described a method of allocation which was not true randomisation and the other seven did not describe the method of randomisation or concealment; our overall rating of the quality of all the included studies was therefore C, that is associated with a high risk of bias. From a recent telephone interview with the clinical investigators by the Chinese Cochrane Center, only 7% of them undertook correct randomisation, while most of them misunderstood the concept of randomisation (<LINK REF="REF-Wu-2006" TYPE="REFERENCE">Wu 2006</LINK>). Through contact with several trialists before inclusion of the trials, we found that some investigators had little knowledge of randomisation design. One trial described as randomised was actually a case-control study. Therefore we could not determine that allocation was truly random and well concealed. Empirical research had proved that inadequate allocation concealment is associated with bias (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>).The result of this meta-analysis could be confounded by possible bias.</P>
<P>Secondly, the included trials were generally of small sample size. None of the trials reported the method of determination of the sample size. The shortcomings of a small sample size is to imply low power of a test. However, no trial appeared to apply any power analysis or mentioned the possibility of a type-II error occurring.</P>
<P>Thirdly, the scheduled treatment period ranged from 10 days to 30 days in the included trials. All the follow ups terminated at the end of the treatment period. The recovery of neurologic deficit occurred quickly in the first three months after symptom onset (<LINK REF="REF-Kotila-1984" TYPE="REFERENCE">Kotila 1984</LINK>). Three months after the onset of stroke would be an appropriate time to measure the neurologic outcome. Therefore we could not determine the long-term effect because of the short period of follow up.</P>
<P>Fourthly, acute stroke trials should use the outcome measures which are relevant to patients to influence clinical practice (<LINK REF="REF-Roberts-1998" TYPE="REFERENCE">Roberts 1998</LINK>). The included trials in this review used the nationally approved outcome measures alone to evaluate the patients neurologic impairment, which was the least clinically relevant to the patients. Handicap or even health-related quality of life outcome measures might be more relevant. However, none of the included trials used these outcome measures.</P>
<P>Furthermore, we have to mention the effect on death. No deaths at the end of the scheduled follow-up period were reported in these trials, which is more important than the neurologic improvement for the stroke patients. In the recent review of trials of traditional Chinese medicines in acute stroke (<LINK REF="REF-Wu-2007" TYPE="REFERENCE">Wu 2007</LINK>), the frequency of death was also extremely low. Therefore, this almost certainly is due to under-reporting, and highlights another major concern about the inadequate quality of these studies.<BR/>
<BR/>Finally, herbal medicine used to be perceived as being natural and harmless in China, but recent literature on the adverse effect of herbal medicine, including dengzhanhua injection, reported allergic reactions, and toxic effects on the liver or renal function (<LINK REF="REF-Zhou-2000" TYPE="REFERENCE">Zhou 2000</LINK>). Therefore we tried to review both the beneficial and adverse effects of dengzhanhua for stroke. However, none of the included trials reported adverse events, which provided insufficient data for us to evaluate the safety of dengzhanhua. From the possible pharmacological action of dengzhanhua, we could not draw a firm conclusion that it does not cause bleeding.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE MODIFIED="2008-04-21 13:27:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>Based on this systematic review, we found no clear evidence that dengzhanhua injection benefits patients with acute cerebral infarction. Even the apparent improvement in neurologic impairment was not reliable because of inadequate randomisation and other methodological weaknesses. Adverse effects were not reported in the trials, so the safety of dengzhanhua is unclear. Due to the generally poor methodological quality and small sample sizes of the included trials, we could not draw any reliable implications for practice.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-04-21 13:28:08 +0100" MODIFIED_BY="Hazel Fraser">
<P>Clinical trials with both high methodological quality and large sample sizes are needed. Sample size should be estimated by the proper statistical method and power or type-II errors should be evaluated. Trials of dengzhanhua for acute cerebral infarction should use more clinically relevant outcome measures and suitable end-points identified to undertake outcome measurements. Furthermore, investigators conducting randomised trials should receive formal training in clinical trial design. From the results of this systematic review, it would be necessary to compare dengzhanhua with placebo or no intervention to discover the definite effect of dengzhanhua for acute cerebral infarction. In addition to the outcome measures for beneficial effects, it is essential to establish a clear monitoring and reporting system for the adverse effects of herbal medicines.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We extend our thanks to the Cochrane Stroke Group Editorial Board for their helpful comments.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-04-17 11:54:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-05-08 14:26:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>All five authors contributed to this review.</P>
<UL>
<LI>Search strategy: Liu, Wu</LI>
<LI>Study selection: Cao, Liu</LI>
<LI>Data extraction: Cao, Liu</LI>
<LI>Quality assessment: Cao, Liu, Wu</LI>
<LI>Statistical and methodological input: Wu, Liu 
</LI>
<LI>Interpretation of data: Cao, Zhong</LI>
<LI>Providing general advice on the review: Liu</LI>
<LI>Writing the review: Cao, Wu</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-04-21 13:33:55 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES MODIFIED="2008-04-21 13:32:50 +0100" MODIFIED_BY="Hazel Fraser">
<INCLUDED_STUDIES MODIFIED="2008-04-21 13:30:19 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Feng-2005" MODIFIED="2008-04-21 13:29:14 +0100" MODIFIED_BY="Hazel Fraser" NAME="Feng 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-04-21 13:29:14 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feng ZW, Hu ZC</AU>
<TI>Curative effect of dengzhanhua injection for acute ischemic stroke</TI>
<SO>Journal of Guangxi Medical University</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>3</NO>
<PG>438-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2005" MODIFIED="2008-04-21 13:29:29 +0100" MODIFIED_BY="Hazel Fraser" NAME="Huang 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-04-21 13:29:29 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang XY, Ding YJ, Fang HW</AU>
<TI>Investigation on the curative effect of dengzhanhua for acute cerebral infarction</TI>
<SO>Modern Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>15</NO>
<PG>1964-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1996" NAME="Li 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li F, Gu DX, Yang SJ, Lu XG</AU>
<TI>Clinical investigation of combination therapy of Chinese Traditional Medicine &amp; Western Medicine for acute cerebral infarction</TI>
<SO>Zhong Xi Yi Jie He Shi Yong Lin Chuang Ji Jiu Zha Zhi</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>5</NO>
<PG>209-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004a" MODIFIED="2008-04-21 13:29:43 +0100" MODIFIED_BY="Hazel Fraser" NAME="Liu 2004a" YEAR="2004">
<REFERENCE MODIFIED="2008-04-21 13:29:43 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu YY, Liu XL, Yang W</AU>
<TI>Curative effect of dengzhanhua injection for acute ischemic stroke</TI>
<SO>Journal of Jinzhou Medical College</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>6</NO>
<PG>68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2005" MODIFIED="2008-04-17 13:01:11 +0100" MODIFIED_BY="Hazel Fraser" NAME="Peng 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-04-17 13:01:11 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peng H, Wen XH</AU>
<TI>Dengzhanxixin for acute ischemic stroke</TI>
<SO>Journal of Clinical Neurology</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>1</NO>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004" MODIFIED="2008-04-21 13:29:57 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wang 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-04-21 13:29:57 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X</AU>
<TI>Clinical observation on dengzhanhua injection for acute ischemic stroke</TI>
<SO>Henan Journal of Practical Nervous Diseases</SO>
<YR>2004</YR>
<VL>7</VL>
<NO>4</NO>
<PG>54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005" MODIFIED="2008-04-17 13:01:40 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wang 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-04-17 13:01:40 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Gu W, Tan F</AU>
<TI>Effect of erigeron injection on platelet level of CD62p and serum content of TNF-alpha and IL-6 in patients with acute cerebral infarction</TI>
<SO>Chinese Journal of Integrated Traditional and Western Medicine/Chung-kuo Chung Hsi</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>4</NO>
<PG>324-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wen-2003" MODIFIED="2008-04-21 13:30:12 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wen 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-04-21 13:30:12 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wen TY</AU>
<TI>Clinical observation on dengzhanhua injection for 39 patients with acute ischemic stroke</TI>
<SO>China Traditional Chinese Medicine Emergency</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>3</NO>
<PG>239</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2005" MODIFIED="2008-04-21 13:30:19 +0100" MODIFIED_BY="Hazel Fraser" NAME="Yu 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-04-21 13:30:19 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu XQ, Zhou J</AU>
<TI>Clinical observation of dengzhanhua injection for 26 patients with acute ischemic stroke</TI>
<SO>Cardiovascular Journal of Chinese Traditional Medicine and Western Medicine</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>10</NO>
<PG>925</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-04-21 13:32:50 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Bai-2002" MODIFIED="2008-04-21 13:30:29 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bai 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-04-21 13:30:29 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bai GH, Li CJ, Xu B</AU>
<TI>Clinical observation on the effect of dengzhanhua injection for acute cerebral infarction</TI>
<SO>Clinical Medicine</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>12</NO>
<PG>56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chu-2003" MODIFIED="2008-04-21 13:30:35 +0100" MODIFIED_BY="Hazel Fraser" NAME="Chu 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-04-21 13:30:35 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chu HB, Lian QR, Zhao GF</AU>
<TI>Curative effect of dengzhanhua injection for 60 cases with acute cerebral infarction</TI>
<SO>Journal of Practical Traditional Chinese lnternal Medicine</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>5</NO>
<PG>416-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fang-1996" MODIFIED="2008-04-21 13:30:47 +0100" MODIFIED_BY="Hazel Fraser" NAME="Fang 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-04-21 13:30:47 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fang DW</AU>
<TI>Curative effect of Yunnan dengzhanhua injection on 106 cases with acute cerebral infarction</TI>
<SO>Zhejiang Zhong Yi Za Zhi</SO>
<YR>1996</YR>
<VL>8</VL>
<PG>381</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2000" MODIFIED="2008-04-21 13:30:58 +0100" MODIFIED_BY="Hazel Fraser" NAME="Li 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-04-21 13:30:58 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Q, Guo YJ</AU>
<TI>Curative effect of naloxone plus dengzhanhua for acute cerebral infarction</TI>
<SO>Yunnan Zhong Yi Zhong Yao Za Zhi</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>3</NO>
<PG>17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-1999" MODIFIED="2008-04-21 13:31:04 +0100" MODIFIED_BY="Hazel Fraser" NAME="Liu 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-04-21 13:31:04 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu RH, Liu HL</AU>
<TI>Clinical investigation on curative effect of dengzhanhua plus citicoline for acute cerebral infarction</TI>
<SO>Lin Chuang Yi Xue</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>7</NO>
<PG>36-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004" MODIFIED="2008-04-21 13:31:13 +0100" MODIFIED_BY="Hazel Fraser" NAME="Liu 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-04-21 13:31:13 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu FR, Bian LZ</AU>
<TI>Curative effect of dengzhanhua on 106 cases with acute cerebral infarction</TI>
<SO>Central Plains Medical Journal</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>12</NO>
<PG>38-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2002" MODIFIED="2008-04-17 13:04:34 +0100" MODIFIED_BY="Hazel Fraser" NAME="Lu 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-04-17 13:04:34 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu YF</AU>
<TI>The clinical observation of erigeron breviscapus hand-mazz injection in the treatment of cerebral infarction</TI>
<SO>Journal of Qiqihar Medical College</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>4</NO>
<PG>362-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2000" MODIFIED="2008-04-21 13:31:26 +0100" MODIFIED_BY="Hazel Fraser" NAME="Sun 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-04-21 13:31:26 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun CP, Ma JJ, XU J</AU>
<TI>Investigation on the curative effect of dengzhanhua for 93 cases with acute cerebral infarction</TI>
<SO>Henan Yi Yao Xin Xi</SO>
<YR>2000</YR>
<VL>8</VL>
<NO>2</NO>
<PG>50-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1987" MODIFIED="2008-04-17 13:07:32 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wang 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-04-17 13:07:32 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang H, Shi M, Yang C, Li J</AU>
<TI>Clinical observation on the therapeutic effect of deng-zan-hua-su-pian on cerebrovascular diseases</TI>
<SO>Journal of Apoplexy and Nervous Diseases</SO>
<YR>1987</YR>
<VL>4</VL>
<NO>4</NO>
<PG>247-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-1999" MODIFIED="2008-04-21 13:32:36 +0100" MODIFIED_BY="Hazel Fraser" NAME="Xu 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-04-21 13:32:36 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu YL, Chen XY</AU>
<TI>Investigation on curative effect of dengzhanhua for 34 cases with acute cerebral infarction</TI>
<SO>Zhong Guo Xiang Chun Yi Sheng Za Zhi</SO>
<YR>1999</YR>
<VL>3</VL>
<PG>23-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2000" MODIFIED="2008-04-21 13:32:43 +0100" MODIFIED_BY="Hazel Fraser" NAME="Yang 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-04-21 13:32:43 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang SH</AU>
<TI>Investigation on curative effect of dengzhanhua plus shenmai injection for acute cerebral infarction</TI>
<SO>Journal of Jingganshan Medical College</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>3</NO>
<PG>95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2002" MODIFIED="2008-04-21 13:32:50 +0100" MODIFIED_BY="Hazel Fraser" NAME="Zhang 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-04-21 13:32:50 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang SF, He MD, Li C</AU>
<TI>Clinical curative effect of dengzhanhua injection on acute cerebral infarction: a report of 100 cases</TI>
<SO>Hunan Yi Ke Da Xue Xue Bao</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>3</NO>
<PG>235-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-04-21 13:33:55 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2008-04-21 13:33:55 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Adams-2003" NAME="Adams 2003" TYPE="JOURNAL_ARTICLE">
<AU>Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, et al</AU>
<TI>Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association</TI>
<SO>Stroke</SO>
<YR>2003</YR>
<VL>34</VL>
<PG>1056-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-AHA-2004" NAME="AHA 2004" TYPE="OTHER">
<AU>American Heart Association</AU>
<TI>New stats show heart disease still America's No. 1 killer, stroke No. 3</TI>
<SO>http://www.americanheart.org/presenter.jhtml?identifier=3018015 (accessed 15 February 2005)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-1998" NAME="Chen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Chen XX</AU>
<TI>Protection effect of dengzhanhua on ATPase activity in the ischemic-reperfusion rat brain</TI>
<SO>Zhong Yao Xin Yao Yu Lin Chuang Yao Li</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>4</NO>
<PG>214</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldman-2000" NAME="Goldman 2000" TYPE="BOOK">
<AU>Goldman L, Ausiello D</AU>
<SO>Cecil Textbook of Medicine</SO>
<YR>2000</YR>
<PB>WB Saunders Company</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gubitz-2004" MODIFIED="2008-04-17 11:43:42 +0100" MODIFIED_BY="Hazel Fraser" NAME="Gubitz 2004" TYPE="COCHRANE_REVIEW">
<AU>Gubitz G, Sandercock P, Counsell C</AU>
<TI>Anticoagulants for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-04-17 11:43:42 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-04-17 11:43:42 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000024.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-He-2004" NAME="He 2004" TYPE="JOURNAL_ARTICLE">
<AU>He W, Liu YM, Chen H, Zeng FD</AU>
<TI>Effect of breviscapine on brain edema and neutrophil infiltration induced by focal cerebral ischemia and reperfusion in rats</TI>
<SO>Chinese Journal of Pharmacology and Toxicology</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>3</NO>
<PG>161-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2008-04-17 13:32:19 +0100" MODIFIED_BY="Hazel Fraser" NAME="Higgins 2005" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>The Cochrane Library</SO>
<YR>2005</YR>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hommel-1995" NAME="Hommel 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Berson G, et al</AU>
<TI>Termination of trial of streptokinase in severe acute ischaemic stroke</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>345</VL>
<PG>57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeffrey-2005" NAME="Jeffrey 2005" TYPE="OTHER">
<AU>Jeffrey LA</AU>
<TI>Stroke, Ischemic</TI>
<SO>http://www.emedicine.com/EMERG/topic558.htm (accessed 9 May 2005)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kotila-1984" MODIFIED="2008-04-17 13:09:49 +0100" MODIFIED_BY="Hazel Fraser" NAME="Kotila 1984" TYPE="JOURNAL_ARTICLE">
<AU>Kotila M, Waltimo O, Niemi ML, Laaksonen R, Lempinen M</AU>
<TI>The profile of recovery from stroke and factors influencing outcome</TI>
<SO>Stroke</SO>
<YR>1984</YR>
<VL>15</VL>
<PG>1039-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MOH-PRC-1999" MODIFIED="2008-04-17 13:09:59 +0100" MODIFIED_BY="Hazel Fraser" NAME="MOH PRC 1999" TYPE="OTHER">
<TI>Chinese Health Statistical Digest</TI>
<SO>Ministry of Health, Peoples Republic of China</SO>
<YR>1999</YR>
<PG>69-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-04-17 13:10:22 +0100" MODIFIED_BY="Hazel Fraser" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NINDS-1995" NAME="NINDS 1995" TYPE="JOURNAL_ARTICLE">
<AU>National Institute of Neurological Disorders and Stroke rt-PA Study Group</AU>
<TI>Tissue plasminogen activator for the treatment of acute ischaemic stroke</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>333</VL>
<PG>1581-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ren-2002" MODIFIED="2008-04-17 13:11:42 +0100" MODIFIED_BY="Hazel Fraser" NAME="Ren 2002" TYPE="BOOK_SECTION">
<AU>Ren DQ</AU>
<TI>Breviscapine tablets</TI>
<SO>Clinical Practical Using Chinese Herbal Preparations</SO>
<YR>2002</YR>
<PG>669-70</PG>
<EN>1st</EN>
<PB>People's Health Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-1998" MODIFIED="2008-04-17 13:12:12 +0100" MODIFIED_BY="Hazel Fraser" NAME="Roberts 1998" TYPE="JOURNAL_ARTICLE">
<AU>Roberts L, Counsell C</AU>
<TI>Assessment of clinical outcomes in acute stroke trials</TI>
<SO>Stroke</SO>
<YR>1998</YR>
<VL>29</VL>
<PG>986-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vila-2000" NAME="Vila 2000" TYPE="JOURNAL_ARTICLE">
<AU>Vila N, Castillo J, Davalos A, Chamorro A</AU>
<TI>Proinflammatory cytokines and early neurological worsening in ischemic stroke</TI>
<SO>Stroke</SO>
<YR>2000</YR>
<VL>31</VL>
<NO>10</NO>
<PG>2325-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-1989" NAME="Wang 1989" TYPE="JOURNAL_ARTICLE">
<AU>Wang ZY</AU>
<TI>Inhibitory effects of new breviscapine on thrombosis in vivo</TI>
<SO>Zhong Xi Yi Jie He Za Zhi</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>1</NO>
<PG>26-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2005" MODIFIED="2008-04-17 13:12:43 +0100" MODIFIED_BY="Hazel Fraser" NAME="WHO 2005" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Global burden of stroke</TI>
<SO>http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf (accessed 21 April 2005)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2006" MODIFIED="2008-04-17 13:12:57 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wu 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wu TX, Li YP, Yao X, Li J</AU>
<TI>Clinical trial registration:to improve the quality of clinical research in China</TI>
<SO>Chinese Journal of Evidence-based Medicine</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>3</NO>
<PG>153-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2007" MODIFIED="2008-04-17 13:13:14 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wu 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wu B, Liu M, Liu H, Li W, Tan S, Zhang S, et al</AU>
<TI>Meta-analysis of traditional Chinese patent medicine for ischemic stroke</TI>
<SO>Stroke</SO>
<YR>2007</YR>
<VL>38</VL>
<NO>6</NO>
<PG>1973-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-2001" NAME="Yang 2001" TYPE="JOURNAL_ARTICLE">
<AU>Yang WY</AU>
<TI>Measurment of scutellarin in the erigeron breviscapus by HPLC</TI>
<SO>Journal of Chengdu University of Traditional Chinese Medicine</SO>
<YR>2001</YR>
<VL>24</VL>
<PG>37-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2000" MODIFIED="2008-04-21 13:33:55 +0100" MODIFIED_BY="Hazel Fraser" NAME="Zhang 2000" TYPE="JOURNAL_ARTICLE">
<AU>Zhang WD, Kong DM</AU>
<TI>Research on chemical component of flavonoid glycoside in dengzhanhua</TI>
<SO>Chinese Herbal Medicine</SO>
<YR>2000</YR>
<VL>31</VL>
<NO>8</NO>
<PG>565-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhou-2000" MODIFIED="2008-04-17 13:13:34 +0100" MODIFIED_BY="Hazel Fraser" NAME="Zhou 2000" TYPE="JOURNAL_ARTICLE">
<AU>Zhou XH, Hua W</AU>
<TI>Dengzhanhua injection cause allergic reaction</TI>
<SO>Adverse Effect of Drug Journal</SO>
<YR>2000</YR>
<VL>2</VL>
<NO>1</NO>
<PG>61</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-04-17 11:46:10 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Cao-2006" MODIFIED="2008-04-17 11:46:10 +0100" MODIFIED_BY="Hazel Fraser" NAME="Cao 2006" TYPE="COCHRANE_REVIEW">
<AU>Cao W, Liu W, Wu T</AU>
<TI>Dengzhanhua preparations for acute cerebral infarction. (Protocol)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-04-17 11:45:58 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-04-17 11:45:58 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="Art. No.: CD005568. DOI: 10.1002/14651858.CD005568"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-04-21 13:28:49 +0100" MODIFIED_BY="Hazel Fraser">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-04-21 13:28:49 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-04-21 13:28:15 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Feng-2005">
<CHAR_METHODS MODIFIED="2008-04-17 12:11:38 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT, method of randomisation and concealment not stated<BR/>Losses to FU: none<BR/>Blinding: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-17 12:11:45 +0100" MODIFIED_BY="Hazel Fraser">
<P>Country: China<BR/>108 patients (acute ischaemic stroke)<BR/>100% CT scan before entry<BR/>Comparability: age similar, more males than females<BR/>Numbers of severity of stroke not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-21 13:28:15 +0100" MODIFIED_BY="Hazel Fraser">
<P>T: dengzhanhua 40 ml once a day for 30 days + routine treatment<BR/>C: routine treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The proportion of patients with marked neurologic improvement at 30 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-17 12:12:07 +0100" MODIFIED_BY="Hazel Fraser">
<P>FU: 30 days<BR/>Quality grading: C (high risk of bias)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-21 13:28:23 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Huang-2005">
<CHAR_METHODS MODIFIED="2008-04-17 12:12:17 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT, method of randomisation and concealment not stated<BR/>Losses to FU: none<BR/>Blinding: not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-17 12:13:47 +0100" MODIFIED_BY="Hazel Fraser">
<P>Country: China<BR/>60 patients (acute ischaemic stroke)<BR/>100% CT scan before entry<BR/>Comparability: age similar, more males than females<BR/>Numbers of severity of stroke: mild - 4 participants in each group; moderate - 13 participants in treatment group,12 participants in control group; severe - 13 participants in treatment group,14 participants in control group</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-21 13:28:23 +0100" MODIFIED_BY="Hazel Fraser">
<P>T: dengzhanhua 40 ml once a day for 14 days + routine treatment<BR/>C: routine treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The proportion of patients with marked neurologic improvement at 14 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-17 12:21:10 +0100" MODIFIED_BY="Hazel Fraser">
<P>FU: 14 days<BR/>Quality grading: C (high risk of bias)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-21 13:28:29 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Li-1996">
<CHAR_METHODS MODIFIED="2008-04-17 12:14:20 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT, method of randomisation and concealment not stated<BR/>Losses to FU: none<BR/>Blinding: not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-17 12:14:30 +0100" MODIFIED_BY="Hazel Fraser">
<P>Country: China<BR/>80 patients (acute ischaemic stroke)<BR/>100% CT or MRI scan before entry<BR/>Comparability: age similar, more females than males<BR/>Numbers of severity of stroke not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-21 13:28:29 +0100" MODIFIED_BY="Hazel Fraser">
<P>T: dengzhanhua 16 ml once a day for 10 days + routine treatment<BR/>C: routine treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The proportion of patients with marked neurologic improvement at 10 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-17 12:21:07 +0100" MODIFIED_BY="Hazel Fraser">
<P>FU: 10 days<BR/>Quality grading: C (high risk of bias)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-21 13:28:33 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Liu-2004a">
<CHAR_METHODS MODIFIED="2008-04-17 12:15:41 +0100" MODIFIED_BY="Hazel Fraser">
<P>Quasi-RCT, method of randomisation: the sequence of admission, concealment not stated<BR/>Losses to FU: none<BR/>Blinding: not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-17 12:15:45 +0100" MODIFIED_BY="Hazel Fraser">
<P>Country: China<BR/>106 patients (acute ischaemic stroke)<BR/>100% CT or MRI scan before entry<BR/>Comparability: age similar, more males than females<BR/>Numbers of severity of stroke not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-21 13:28:33 +0100" MODIFIED_BY="Hazel Fraser">
<P>T: dengzhanhua 75 mg once a day for 14 days + routine treatment<BR/>C: routine treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The proportion of patients with marked neurologic improvement at 14 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-17 12:21:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>FU: 14 days<BR/>Quality grading: C (high risk of bias)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-21 13:28:36 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Peng-2005">
<CHAR_METHODS MODIFIED="2008-04-17 12:16:10 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT, method of randomisation and concealment not stated<BR/>Losses to FU: none<BR/>Blinding: not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-17 12:16:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>Country: China<BR/>66 patients (acute ischaemic stroke)<BR/>100% CT or MRI scan before entry<BR/>Comparability: age similar, more males than females<BR/>Numbers of severity of stroke not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-21 13:28:36 +0100" MODIFIED_BY="Hazel Fraser">
<P>T: dengzhanhua 40 ml once a day for 14 days + routine treatment<BR/>C: routine treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The proportion of patients with marked neurologic improvement at 14 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-17 12:20:59 +0100" MODIFIED_BY="Hazel Fraser">
<P>FU: 14 days<BR/>Quality grading: C (high risk of bias)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-21 13:28:39 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Wang-2004">
<CHAR_METHODS MODIFIED="2008-04-17 12:16:36 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT, method of randomisation and concealment not stated<BR/>Losses to FU: none<BR/>Blinding: not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-17 12:17:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>Country: China<BR/>120 patients (acute ischaemic stroke)<BR/>100% CT scan before entry<BR/>Comparability: age similar, more males than females<BR/>Numbers of severity of stroke: mild - 20 participants in treatment group,18 participants in control group; moderate - 32 participants in treatment group, 28 participants in control group; severe - 12 participants in treatment group,10 participants in control group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-21 13:28:39 +0100" MODIFIED_BY="Hazel Fraser">
<P>T: dengzhanhua 30 mg once a day for 30 days + routine treatment<BR/>C: routine treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The proportion of patients with marked neurologic improvement at 30 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-17 12:20:53 +0100" MODIFIED_BY="Hazel Fraser">
<P>FU: 30 days<BR/>Quality grading: C (high risk of bias)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-21 13:28:42 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Wang-2005">
<CHAR_METHODS MODIFIED="2008-04-17 12:18:21 +0100" MODIFIED_BY="Hazel Fraser">
<P>Quasi-RCT, method of randomisation: the sequence of admission, concealment not stated<BR/>Losses to FU: none<BR/>Blinding: not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-17 12:18:27 +0100" MODIFIED_BY="Hazel Fraser">
<P>Country: China<BR/>68 patients (acute ischaemic stroke)<BR/>100% CT or MRI scan before entry<BR/>Comparability: age similar, more males than females<BR/>Numbers of severity of stroke not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-21 13:28:42 +0100" MODIFIED_BY="Hazel Fraser">
<P>T: dengzhanhua 40 ml once a day for 15 days + routine treatment<BR/>C: routine treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The proportion of patients with marked neurologic improvement at 15 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-17 12:20:47 +0100" MODIFIED_BY="Hazel Fraser">
<P>FU: 15 days<BR/>Quality grading: C (high risk of bias)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-21 13:28:46 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Wen-2003">
<CHAR_METHODS MODIFIED="2008-04-17 12:18:57 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT, method of randomisation and concealment not stated<BR/>Losses to FU: none<BR/>Blinding: not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-17 12:19:51 +0100" MODIFIED_BY="Hazel Fraser">
<P>Country: China<BR/>69 patients (acute ischaemic stroke)<BR/>100% CT scan before entry<BR/>Comparability: age similar, more males than females<BR/>Numbers of severity of stroke: mild - 14 participants in treatment group,11 participants in control group; moderate - 16 participants in treatment group,12 participants in control group; severe - 9 participants in treatment group,7 participants in control group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-21 13:28:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>T: dengzhanhua 30 ml once a day for 28 days + routine treatment<BR/>C: routine treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The proportion of patients with marked neurologic improvement at 28 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-17 12:20:28 +0100" MODIFIED_BY="Hazel Fraser">
<P>FU: 28 days<BR/>Quality grading: C (high risk of bias)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-21 13:28:49 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Yu-2005">
<CHAR_METHODS MODIFIED="2008-04-17 12:20:12 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT, method of randomisation and concealment not stated<BR/>Losses to FU: none<BR/>Blinding: not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-17 12:20:17 +0100" MODIFIED_BY="Hazel Fraser">
<P>Country: China<BR/>46 patients (acute ischaemic stroke)<BR/>100% CT or MRI scan before entry<BR/>Comparability: age similar, more females than males<BR/>Numbers of severity of stroke not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-21 13:28:49 +0100" MODIFIED_BY="Hazel Fraser">
<P>T: dengzhanhua 40 ml once a day for 30 days + routine treatment<BR/>C: routine treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The proportion of patients with marked neurologic improvement at 30 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-17 12:20:37 +0100" MODIFIED_BY="Hazel Fraser">
<P>FU: 30 days<BR/>Quality grading: C (high risk of bias)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Routine treatment/therapy: mannitol; management of blood glucose, blood pressure, and antibiotics; no thrombolytic therapy was applied<BR/>C: control group<BR/>CT: computerised tomography<BR/>FU: follow up<BR/>MRI: magnetic resonance imaging<BR/>RCT: randomised controlled trial<BR/>T: treatment group</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bai-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dengzhanhua compared with unproven drug</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chu-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dengzhanhua compared with unproven drug</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fang-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dengzhanhua compared with unproven drug</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Confounded with naloxone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liu-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dengzhanhua compared with unproven drug</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liu-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dengzhanhua compared with unproven drug</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lu-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dengzhanhua compared with unproven drug</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sun-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dengzhanhua compared with unproven drug</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dengzhanhua compared with unproven drug</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Xu-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dengzhanhua compared with unproven drug</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yang-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Confounded with Shenmai</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhang-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dengzhanhua compared with unproven drug</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Feng-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Li-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Liu-2004a">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Peng-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wang-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Wang-2005">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wen-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yu-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-04-21 13:19:06 +0100" MODIFIED_BY="Hazel Fraser">
<COMPARISON ID="CMP-001" MODIFIED="2008-04-21 13:19:06 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<NAME>Dengzhanhua versus other drugs</NAME>
<DICH_OUTCOME CHI2="7.646504410785195" CI_END="1.721789394309059" CI_START="1.3633827464138788" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5321416230751561" ESTIMABLE="YES" EVENTS_1="279" EVENTS_2="152" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.23598002837018975" LOG_CI_START="0.13461779370772273" LOG_EFFECT_SIZE="0.1852989110389562" METHOD="MH" MODIFIED="2008-04-21 13:19:06 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="0.4687395600503823" P_Q="0.0" P_Z="7.723962761591363E-13" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="382" TOTAL_2="341" WEIGHT="99.99999999999999" Z="7.165966559838006">
<NAME>Marked neurologic improvement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.646504410785195" CI_END="1.721789394309059" CI_START="1.3633827464138788" DF="8.0" EFFECT_SIZE="1.5321416230751561" ESTIMABLE="YES" EVENTS_1="279" EVENTS_2="152" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.23598002837018975" LOG_CI_START="0.13461779370772273" LOG_EFFECT_SIZE="0.1852989110389562" MODIFIED="2008-04-21 13:19:06 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="0.4687395600503823" P_Z="7.723962761591363E-13" STUDIES="9" TAU2="0.0" TOTAL_1="382" TOTAL_2="341" WEIGHT="99.99999999999999" Z="7.165966559838006">
<NAME>Dengzhanhua plus routine therapy versus routine therapy</NAME>
<DICH_DATA CI_END="2.817164547435364" CI_START="1.0551927497234947" EFFECT_SIZE="1.7241379310344827" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="15" LOG_CI_END="0.4498122143823443" LOG_CI_START="0.023331798491781117" LOG_EFFECT_SIZE="0.23657200643706267" ORDER="13406" O_E="0.0" SE="0.25051670740622306" STUDY_ID="STD-Feng-2005" TOTAL_1="58" TOTAL_2="50" VAR="0.06275862068965517" WEIGHT="5.648773577891041"/>
<DICH_DATA CI_END="2.2274512125560806" CI_START="0.9657275988741559" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="15" LOG_CI_END="0.3478082005429334" LOG_CI_START="-0.015145357009883412" LOG_EFFECT_SIZE="0.16633142176652496" ORDER="13407" O_E="0.0" SE="0.21320071635561044" STUDY_ID="STD-Huang-2005" TOTAL_1="30" TOTAL_2="30" VAR="0.04545454545454546" WEIGHT="7.7992032434054215"/>
<DICH_DATA CI_END="3.0368790584295042" CI_START="1.1018622810569152" EFFECT_SIZE="1.829268292682927" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.4824274967906538" LOG_CI_START="0.04212731655327537" LOG_EFFECT_SIZE="0.26227740667196453" ORDER="13408" O_E="0.0" SE="0.25863450539247906" STUDY_ID="STD-Li-1996" TOTAL_1="41" TOTAL_2="39" VAR="0.06689180737961228" WEIGHT="5.2997407638391865"/>
<DICH_DATA CI_END="2.961369444884189" CI_START="1.378799359043783" EFFECT_SIZE="2.0206766917293235" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="19" LOG_CI_END="0.471492591065705" LOG_CI_START="0.13950107284744695" LOG_EFFECT_SIZE="0.305496831956576" ORDER="13409" O_E="0.0" SE="0.19501346118592414" STUDY_ID="STD-Liu-2004a" TOTAL_1="56" TOTAL_2="50" VAR="0.03803025004371394" WEIGHT="9.321769852396944"/>
<DICH_DATA CI_END="4.136565674217057" CI_START="1.193809549723384" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.6166399237978445" LOG_CI_START="0.07693504865146812" LOG_EFFECT_SIZE="0.3467874862246563" ORDER="13410" O_E="0.0" SE="0.3170253152432002" STUDY_ID="STD-Peng-2005" TOTAL_1="33" TOTAL_2="33" VAR="0.10050505050505049" WEIGHT="3.5272778487763228"/>
<DICH_DATA CI_END="1.7538539721408943" CI_START="1.1865304752011778" EFFECT_SIZE="1.4425675675675675" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="37" LOG_CI_END="0.24399343068708382" LOG_CI_START="0.07427889724508675" LOG_EFFECT_SIZE="0.15913616396608526" ORDER="13411" O_E="0.0" SE="0.0996911570443186" STUDY_ID="STD-Wang-2004" TOTAL_1="64" TOTAL_2="56" VAR="0.009938326792834996" WEIGHT="35.67091782413438"/>
<DICH_DATA CI_END="2.90753485724899" CI_START="1.1307332778205141" EFFECT_SIZE="1.8131868131868132" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.4635249300110266" LOG_CI_START="0.05336017377459871" LOG_EFFECT_SIZE="0.2584425518928127" ORDER="13412" O_E="0.0" SE="0.2409328081615662" STUDY_ID="STD-Wang-2005" TOTAL_1="35" TOTAL_2="33" VAR="0.058048618048618064" WEIGHT="6.107109010583065"/>
<DICH_DATA CI_END="1.6952020830518855" CI_START="1.0257894546168262" EFFECT_SIZE="1.3186813186813187" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="21" LOG_CI_END="0.22922147736093984" LOG_CI_START="0.011058230092122529" LOG_EFFECT_SIZE="0.12013985372653123" ORDER="13413" O_E="0.0" SE="0.1281501713711941" STUDY_ID="STD-Wen-2003" TOTAL_1="39" TOTAL_2="30" VAR="0.01642246642246642" WEIGHT="21.58684507045976"/>
<DICH_DATA CI_END="2.1993476516392074" CI_START="0.7775301782431259" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.34229388386507476" LOG_CI_START="-0.10928274572220043" LOG_EFFECT_SIZE="0.11650556907143717" ORDER="13414" O_E="0.0" SE="0.26525834755993305" STUDY_ID="STD-Yu-2005" TOTAL_1="26" TOTAL_2="20" VAR="0.07036199095022623" WEIGHT="5.038362808513881"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-04-17 11:51:37 +0100" MODIFIED_BY="Hazel Fraser">
<APPENDIX ID="APP-01" MODIFIED="2008-04-17 11:51:37 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2008-04-17 11:51:04 +0100" MODIFIED_BY="Hazel Fraser">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-04-17 11:51:37 +0100" MODIFIED_BY="Hazel Fraser">
<P>The following search strategy was used for MEDLINE (Ovid) and was modified to suit the other databases.<BR/>

<BR/>
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp cerebrovascular accident/ or exp hypoxia-ischemia, brain/ or exp intracranial arterial diseases/ or exp "intracranial embolism and thrombosis"/<BR/>2. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$ or apoplexy)).tw.<BR/>3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.<BR/>4. 1 or 2 or 3<BR/>5. plant extracts/ or drugs, Chinese herbal/<BR/>6. phytotherapy/ or plants/ or plants, medicinal/ or asteraceae/<BR/>7. (dengzhanhua$ or deng zhan hua$ or deng-zhan-hua$).tw.<BR/>8. (dengzhanxixin$ or deng zhan xi xin$ or deng-zhan-xi-xin$).tw.<BR/>9. (erigero$ or breviscap$ or yimaikang or scutellarin or fleabane).tw.<BR/>10. 5 or 6 or 7 or 8 or 9<BR/>11. 4 and 10</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>